Drug
Canakinumab clinical trials
Also written ACZ885 and Ilaris.
- studies test it
- 100
- open now
- 6
- in phase 3
- 33
- first study started
- 2003
Keep track of what changes. Save the canakinumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
100 studies that test it; most in 2010 (11)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 7 |
| 2008 | 4 |
| 2009 | 9 |
| 2010 | 11 |
| 2011 | 11 |
| 2012 | 6 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 6 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 6 |
| 2020 | 5 |
| 2021 | 8 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 15
- Phase 2
- 58
- Phase 3
- 33
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- Gout
- 4
Who runs them
Industry 67 · Other 33
Novartis Pharmaceuticals (50) · Novartis (17) · University Hospital, Basel, Switzerland (3) · Charite University, Berlin, Germany (3) · NYU Langone Health (2) · University of Zurich (2) · M.D. Anderson Cancer Center (2) · Wei-Che Ko (1)
Often tested with
Tested in the same studies.
Secukinumab (4) · Spartalizumab (3) · Adalimumab (2) · Ustekinumab (2) · Guselkumab (2) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · Gemcitabine (2)
Studies
Open first, then newest update. How each study uses canakinumab is read from its arms, and is right about nine times in ten.
Testing it · 100
- Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal HematopoiesisRecruitingPhase 2Massachusetts General HospitalNCT06691217Written as CANAKINUMAB (ILARIS®)
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Canakinumab
- Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung TrialRecruitingPhase 2M.D. Anderson Cancer CenterNCT04789681Written as Canakinumab
- A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT04239157Written as Canakinumab
- Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT StudyRecruitingPhase 2Uma BorateNCT05641831Written as Canakinumab
- Canakinumab for the Treatment of Postprandial HypoglycemiaRecruitingPhase 3University Hospital, Basel, SwitzerlandNCT05401578Written as Canakinumab
- A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT04905316Written as Canakinumab
- Evaluation of Canakinumab in High-Risk Former-SmokersCompletedPhase 2Peter ShieldsNCT06038526Written as Canakinumab
- Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC SubjectsTerminatedPhase 3Novartis PharmaceuticalsNCT03631199Written as canakinumab
- Using a Contact Dermatitis Model With Biologic Medications to Study Skin InflammationActive, not recruitingPhase 2/3Wei-Che KoNCT05535738Written as Canakinumab
- Study of Canakinumab in Patients With MyelofibrosisActive, not recruitingPhase 2John MascarenhasNCT05467800Written as Canakinumab
- A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell CarcinomaCompletedEarly Phase 1Columbia UniversityNCT04028245Written as Canakinumab
- Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSDCompletedPhase 3Novartis PharmaceuticalsNCT04717635Written as Canakinumab
- A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic CancerActive, not recruitingPhase 1NYU Langone HealthNCT05984602Written as Canakinumab
- Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell AnemiaCompletedPhase 2Novartis PharmaceuticalsNCT02961218Written as ACZ885
- Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESAActive, not recruitingPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT04798339Written as Canakinumab Injection
- A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)TerminatedPhase 2Novartis PharmaceuticalsNCT04814368Written as canakinumab
- Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's DiseaseTerminatedPhase 2Novartis PharmaceuticalsNCT04795466Written as Canakinumab
- Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDSTerminatedPhase 1Novartis PharmaceuticalsNCT04810611Written as canakinumab
- Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).TerminatedPhase 1Novartis PharmaceuticalsNCT03742349Written as canakinumab
See all 100 studies that test canakinumab →
Given in every arm · 2 — canakinumab is usual care beside what is tested
- Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaCompletedPhase 2Novartis PharmaceuticalsNCT03484923Written as ACZ885
- PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC PatientsTerminatedPhase 1Novartis PharmaceuticalsNCT03064854Written as Canakinumab
As the comparator · 2 — what is tested is compared with canakinumab
- An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's DiseaseCompletedPhase 3AO GENERIUMNCT06497491Written as Ilaris®
- A Safety, Pharmacokinetics and Pharmacodynamics Study of GNR-086 and Ilaris® in Healthy VolunteersCompletedPhase 1AO GENERIUMNCT06481189Written as Ilaris®
Codes
What other systems call canakinumab · ClinicalTrials.gg INT005441
- MeSH (NLM) C541220canakinumabConfirmed NLM, Wikidata
- UNII (FDA) 37CQ2C7X93CANAKINUMABConfirmed FDA, NLM, Wikidata
- RxNorm 853491Confirmed FDA, Wikidata
- Wikidata Q3655009canakinumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80971CanakinumabOne source FDA
- DrugBank DB06168One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C541220 | canakinumab | Confirmed NLM, Wikidata |
| UNII (FDA) | 37CQ2C7X93 | CANAKINUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 853491 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3655009 | canakinumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80971 | Canakinumab | One source FDA |
| DrugBank | DB06168 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.